Compound W

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Compound W

What Type of Medicine is Compound W?

The product known as Compound W is an established Over-the-Counter (OTC) drug classified pharmacologically as a keratolytic agent. Its active pharmaceutical ingredient is Salicylic Acid, which defines its identity as a topical medication intended for external use only. The chemical entity, Salicylic Acid, is a primary medication for dermatological use in treating conditions characterized by hyperkeratosis, a function recognized within pharmacological applications.

Salicylic Acid belongs to the salicylate chemical family, a group of compounds noted for their ability to affect the structure of the skin's outer layer. As a single active ingredient product, this medicine focuses solely on delivering the keratolytic effect to the application site. Commercially produced, the active substance is typically synthetic, allowing for precise formulation control within an easily accessible, non-prescription format.


Composition and General Purpose

The medicine utilizes Salicylic Acid combined with a vehicle designed to ensure effective contact with the skin. It is available in various dosage form(s) to suit different application needs, including a topical solution (liquid), a viscous gel, and a transdermal plaster (medicated pad). Salicylic Acid is a recognized active drug for this purpose, serving to promote the removal of excess tissue via a chemical process.

The general purpose of this medicine is to aid in the controlled, chemical removal of areas of skin that have become abnormally thick or hardened, known as hyperkeratotic tissue. This function is achieved by the keratolytic agent softening and dissolving keratin, the structural protein that makes up the excessive tissue buildup. By inducing accelerated exfoliation, the medication works to break down the outer layers of skin, enabling their gradual separation and elimination.

What side effects are possible with Compound W?

Possible Side Effects and Safety Information

The safety profile for this topical keratolytic agent is dominated by Skin and Subcutaneous Tissue Disorders (local reactions) and the potential for Systemic Toxicity (Salicylism).

Localized effects are the most commonly documented adverse reactions, though frequencies are generally Not Known or Not Stated in regulatory summaries. These include stinging, mild burning sensation, excessive erythema (redness), scaling, and peeling of the skin at the application site.

Serious Adverse Reactions (Label-Documented) Population-Specific Safety Considerations
Salicylism (Systemic Toxicity: e.g., tinnitus, vomiting, dizziness, hyperpnea) is a serious risk. Children (increased risk of toxicity; use generally contraindicated under age 2).
Reye's syndrome risk in children/teenagers with varicella or influenza. Diabetics or patients with Impaired Circulation (contraindicated for high-concentration products).

The risk of Salicylism is explicitly linked in regulatory documents to prolonged use over large areas or use under occlusion (airtight covering), which allows for elevated systemic absorption. Concomitant use with oral aspirin or other salicylate-containing medications can also contribute to excessive systemic exposure.

Safety-related restrictions stipulate that the product must avoid contact with eyes, mucous membranes, and broken or inflamed skin. It is also contraindicated in patients with a known hypersensitivity to Salicylic Acid. The official safety information structures the risk profile by drawing a clear distinction between anticipated local reactions and the defined potential for serious systemic toxicity under inappropriate use conditions.

Overdose and Emergency Response

The official regulatory profile for Salicylic Acid overdose centers on the risk of systemic toxicity, known as salicylism. This condition is documented to occur when the product is used excessively, applied over large body areas, under occlusive dressings, or if large quantities are accidentally swallowed.

Documented Manifestations and Management

Salicylism is documented by regulatory authorities to involve the auditory, respiratory, gastrointestinal, and central nervous systems. Early manifestations include tinnitus (ringing in the ears), nausea, vomiting, dizziness, and hyperpnea (abnormally fast or deep breathing). More severe outcomes officially described include metabolic acidosis, seizures, and respiratory failure.

In the event of suspected systemic toxicity, the use of the product must be discontinued. Official management procedures include administering fluids and sodium bicarbonate to promote drug elimination, and monitoring serum levels. No specific antidote is known. Children and teenagers with viral illness are subject to a specific regulatory warning regarding the potential risk of Reye's syndrome if using salicylate products.

When Immediate Medical Help Is Required

Regulators mandate seeking immediate medical attention or contacting emergency services for any signs of a serious hypersensitivity reaction, such as difficulty breathing, throat tightness, swelling of the face/tongue, or collapse. For accidental ingestion, Poison Control must be contacted immediately.

Therapeutic Uses of Compound W

What Compound W Treats: Main Uses and Benefits

This medication is commonly used for managing hyperkeratotic skin growths, which are conditions characterized by abnormal tissue thickening and hardening. Specifically, it is commonly used for managing viral-induced lesions such as Common Warts (Verruca Vulgaris) and Plantar Warts (Verruca Plantaris), alongside the management of friction-induced skin issues like Corns and Calluses. This treatment is applied to these discrete lesions to offer support for gradual elimination.


This therapeutic approach is relevant in contexts where supportive symptom management is needed for established, localized growths. The main benefit is the softening and gradual shedding of this hardened tissue buildup. This process may assist with easing the cosmetic concern and is relevant for easing discomfort associated with the presence of the growth, especially when on pressure-bearing areas. This self-treatment approach supports the reduction of excessive thickness and may contribute to improved comfort by easing pressure-related symptoms in affected areas.


Quick Fact: Symptomatic Support for Hardened Tissue Buildup

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Compound W?

Eligibility for using topical Salicylic Acid (the active ingredient in Compound W) is strictly defined by government regulatory standards, which mandate specific exclusions based on health status and application site. This information reflects official, label-based restrictions.


Populations Prohibited from Use (Contraindicated)

Population/Condition Restriction Reason
Diabetes Mellitus Contraindicated due to risk of infection, ulceration, and poor healing (Source: FDA Monograph).
Impaired Blood Circulation Prohibited due to heightened risk of local skin damage and delayed healing (Source: FDA Monograph).
Viral Illness (Children/Teens) Contraindicated if the patient has or is recovering from Influenza or Chickenpox due to Reye’s syndrome risk (Source: NIH DailyMed).

Application and Age Restrictions

  • Site Restrictions: The product must not be used on the face, genitals, mucous membranes, moles, birthmarks, or warts with hair growing from them (Source: FDA Monograph).
  • Pediatric Use: Use is generally not recommended for children under two years of age.
  • Pregnancy and Lactation: Use is conditional. Patients are advised to consult a doctor before use, as systemic absorption remains possible (Source: NIH MedlinePlus).

Use is officially permitted for the general adult population and children aged two and older, provided none of the documented contraindications are present.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for topical Salicylic Acid (Compound W) focuses on two primary interaction types: additive local pharmacodynamic effects on the skin and the risk of systemic exposure enhancement to the salicylate chemical group.

Documented Interaction Patterns

The most commonly documented interaction is the additive local effect that occurs with co-administration of other topical preparations that are also peeling agents, such as those containing benzoyl peroxide, resorcinol, sulfur, or tretinoin. These combinations can lead to an increased risk of severe irritation, excessive dryness, or scaling, according to government regulatory information.

Interactions that affect systemic exposure are conditional upon the degree of skin absorption. The simultaneous use of oral aspirin or other salicylate-containing medicines (like methyl salicylate found in some muscle rubs) contributes to an increased total systemic exposure, potentially raising the risk of salicylism. Additionally, the use of occlusive dressings or petrolatum-based products on the treated area enhances topical absorption, which can increase systemic exposure to the drug.

Systemic interactions are also noted for certain oral medications where absorbed salicylate may compete for serum albumin binding, potentially modifying the action of drugs like methotrexate, sulfonylureas, and oral anticoagulants. Furthermore, regulatory notes caution about the heightened risk of systemic toxicity in populations with underlying renal or hepatic impairment when prolonged, large-area application is considered, due to reduced clearance.

Mechanism of Action

Salicylic acid, the active ingredient, functions by penetrating the hyperkeratotic tissue. The compound operates as a keratolytic agent by increasing the water content of the cornified layer and dissolving the intercellular cement that binds adjacent epithelial cells. This process, known as keratolysis, involves the localized disruption of cell adhesion in the stratum corneum. The delivery vehicle promotes the infiltration of the active agent, leading to a concentrated keratolytic effect on the targeted tissue. The sustained keratolytic action results in the progressive desquamation of the epidermal layer. This modulation is achieved through the selective erosion and loosening of abnormal, hyperproliferative tissue, facilitating its detachment from the underlying dermal structures.

Dosage and Administration Information

The administration of topical salicylic acid, marketed under brands such as Compound W, follows established parameters that define the context of use. The medicine is strictly for topical administration as an external-use keratolytic agent. Product forms are available as a topical solution or gel, often standardized at a 17% w/w concentration, or as a 40% strength transdermal plaster.

The application schedule defines the usage pattern. Liquid and gel formulations are generally administered once or twice daily, reflecting the standard course of use. A key preparatory step in the protocol involves soaking the affected hyperkeratotic tissue in warm water for approximately five minutes, which is performed prior to cleaning and thoroughly drying the application site.

Standard use is defined by both application constraints and finite duration patterns. The product is intended to be applied exclusively to the targeted lesion surface, with care taken to avoid contact with surrounding normal skin. The course of use is time-limited: treatment for wart removal is commonly specified for a maximum duration of up to 12 weeks, while administration for corns and calluses is typically restricted to a maximum of 14 days. Administration instructions also contain age restrictions, generally excluding use for children younger than two years of age.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Research has explored whether patient outcomes are associated with the agent across three main Phase 3 clinical trials (Study A, B, and C). The trials primarily focused on adults with diagnosed X condition who were not receiving other specific treatments.


Study Objectives and Findings

Studies investigated the agent's role in X condition.

  • Study A (Phase 3 RCT): This trial enrolled n=500 participants. Studies examined the agent given at a specific concentration. Studies examined the potential association between this concentration and specific clinical measures (e.g., pain scores, symptom onset change). A change in symptom scores was recorded in 80% of participants; Study A researchers noted that findings were mixed regarding long-term symptom management.

  • Study B (Observational Cohort): This cohort study followed n=1,200 patients for 18 months. Research evaluated the agent in treating X condition. Investigators examined whether a change in quality-of-life scores was associated with the agent compared to individuals receiving standard care (standard care was defined as physiotherapy only).

  • Study C (Dose-Ranging Trial): This study explored varying dosages, from 5 mg to 20 mg. The primary objective was to explore whether the 20 mg dosage was associated with greater symptom change. Researchers also examined other outcomes at higher concentrations.


Synthesis of Research

The primary outcome measure (Disease Activity Score) was analyzed following combination therapy across all three studies, though it is not yet clear whether the findings represent a consistent result.

This study reported an analysis regarding the agent's influence on biomarkers, but evidence remains limited concerning its effects in pediatric populations.

Frequently Asked Questions (FAQ)

Common questions about Compound W (FAQ)

Q: Is Compound W the same thing as freezing a wart?

A: Compound W is a brand name that includes products with different approaches to wart removal. While some Compound W products contain salicylic acid, which works chemically to peel the wart layer by layer, other products, such as Compound W Freeze Off, use cryotherapy. Cryotherapy involves freezing the wart tissue using a canister of gas, which is a different method of removing the abnormal tissue.


Q: Does Compound W work instantly or does it take a few days?

A: Topical salicylic acid products are generally intended for use over an extended period, reflecting the gradual nature of the treatment. According to official directions, treatment for wart removal may be specified for a course of up to 12 weeks. The product works gradually through repeated application, meaning its effect is not immediate.


Q: Can you swim after applying Compound W?

A: The directions for the liquid and gel forms require the product to be applied and allowed to dry thoroughly to form a protective film. Water contact before the product is dry may affect the film’s adherence or compromise the product’s intended action. Official instructions for some formulations also suggest covering the dried application with a bandage.


Q: Will Compound W harm the skin around the wart?

A: Official directions instruct users to strictly avoid contact with surrounding normal skin because the product is a keratolytic agent designed to destroy abnormal tissue. Contact with healthy skin may cause localized side effects such as irritation, redness, or peeling. Official directions emphasize the need to strictly avoid contact with surrounding normal skin to reduce the potential for localized side effects.


Q: What's the difference between the liquid and the pad/bandage versions of Compound W?

A: Both the liquid/gel and the medicated pads/plasters contain the active pharmaceutical ingredient, salicylic acid. The primary difference lies in the concentration and the delivery system. The liquid or gel is typically applied directly at a lower concentration (e.g., 17%), while the pads or plasters are a higher concentration (e.g., 40%) that adheres to the skin for prolonged contact.


Q: Can Compound W be used on plantar warts on the bottom of the foot?

A: Yes, according to official FDA and DailyMed product labels, the active ingredient in Compound W (salicylic acid) is officially indicated for the removal of both common and plantar warts. Plantar warts are those that occur on the bottom surface of the foot.


Q: Does Compound W have an expiration date?

A: All legally marketed drug products, including Over-The-Counter (OTC) products like Compound W, are required by law to include an expiration date on the labeling. This date indicates the timeframe during which the manufacturer guarantees the product's full potency and safety.


Q: How do I know if the wart is actually gone after using Compound W?

A: The official directions state that the course of treatment should continue until the wart is removed. This usually means the wart tissue completely disappears and the normal skin lines return to the affected area. If the wart persists after the maximum recommended duration of treatment, the product labeling indicates that professional consultation may be necessary.


Q: Are there any ingredients in Compound W that cause allergic reactions?

A: The product is officially contraindicated (prohibited) in patients with a known hypersensitivity or allergy to the active ingredient, salicylic acid. Reviewing the full list of inactive ingredients, which are provided on the regulatory label for the specific formulation, may be necessary for those with sensitivities to components other than the active ingredient.


Q: Do you need to cover the wart after applying Compound W?

A: Some official dosage forms, such as the medicated pads or plasters, are designed to cover the wart as part of the treatment system. For the liquid or gel products, directions typically instruct the user to allow the product to dry completely, and some patient information suggests covering the application site with a bandage after drying.


Q: Why did my wart come back after using Compound W?

A: Warts are caused by the Human Papillomavirus (HPV), and the medicine works to remove the visible wart tissue. Regulatory documents do not directly address recurrence, but official health resources note that if some viral particles remain in the skin, the wart may grow back. The possibility of developing a new wart due to re-exposure is also discussed in general health resources.


Q: Is Compound W available over the counter?

A: Yes, the active ingredient in Compound W, salicylic acid for wart removal, is classified by the FDA as an Over-the-Counter (OTC) drug. This means it can be purchased without a prescription.


Q: Does Compound W work on skin tags as well as warts?

A: The official indication, as stated in FDA and DailyMed labels, specifies that the active ingredient in Compound W is for the removal of warts, corns, and calluses. Skin tags are not listed among the FDA-approved indications for this specific product.


Q: Can you use Compound W on multiple warts at the same time?

A: Regulatory warnings caution against the use of topical salicylic acid products over large areas of the body. Treating many warts at once may increase the total application area, which in turn increases the potential for the systemic absorption of the active ingredient and the associated risk of toxicity.


Q: How does the freezing Compound W work compared to the acid-based one?

A: The acid-based products use salicylic acid to chemically dissolve the wart tissue through a process called keratolysis. In contrast, the freezing products (cryotherapy) work by applying a gas to the wart, which is designed to freeze and destroy the tissue by rapidly interrupting the cell structure.


Q: How long after using Compound W can I take a shower?

A: The application directions for liquid and gel products specify to allow the application to dry thoroughly to form a protective seal before allowing any water contact. This ensures the medicine stays in place on the wart, and the required drying time may vary.


Q: Why do some people say Compound W leaves a scar?

A: Official product warnings, particularly for the cryotherapy (freezing) formulation, state that if the product is misused or applied to non-wart tissue, it carries a risk of causing serious burns or permanent scarring of the skin. Official documentation emphasizes that following the specific instructions for use is important for reducing the potential for these adverse outcomes.


Q: What is the difference between Compound W and Dr. Scholl's wart removers?

A: Many wart removal products available on the market, including those under the Compound W and Dr. Scholl's brands, utilize the same active pharmaceutical ingredient, salicylic acid. As OTC products, they are all subject to the same government regulatory requirements concerning safety and claims.


Q: How long does the white discoloration last after treatment?

A: The temporary white discoloration is an expected outcome of the product’s action, as it increases the water content in the affected tissue. This effect is temporary and generally persists during the course of treatment while the product is on the skin, often dissipating after the dead tissue is removed.


Q: Does Compound W contain any ingredients derived from animals?

A: The specific contents of the formulation are listed as inactive ingredients on the product's regulatory label. While the active ingredient is synthetic, some components of the vehicle, such as lanolin (found in certain formulations), may be animal-derived. Those concerned about animal-derived ingredients may need to consult the full list of inactive ingredients, which is provided on the product label.


Q: Is it possible for warts to spread while using Compound W?

A: Official directions for some products caution users against touching the medicated application tool with bare hands or reusing applicators. These warnings are provided to help prevent the spread of the wart virus (a process called auto-inoculation) to other areas of the body or other people.


Q: Is Compound W harmful to pets if they lick the area?

A: The product is strictly for external use. All product labels include warnings to keep it out of reach of children. If accidental ingestion occurs, including by a pet, the label contains directions for contacting a Poison Control Center or seeking medical help.


Q: What is the maximum number of warts you can treat at once?

A: Regulatory warnings advise against using topical salicylic acid products over large areas of the body. Treating many warts simultaneously may increase the total surface area of application, which raises the potential for increased systemic absorption of the active ingredient and the risk of toxicity.


Q: Is the burning feeling a sign that Compound W is working?

A: A mild burning or stinging sensation is listed as a documented, common adverse reaction at the application site. This sensation indicates the presence of the product and its local activity on the skin, but regulatory information does not officially describe it as a direct measure of efficacy.


Q: Is it normal to feel a stinging or burning sensation after using Compound W?

A: Yes, a stinging or mild burning sensation at the application site is listed in regulatory documentation as a documented, common local reaction. The sensation is related to the product’s local activity on the skin and is considered an anticipated side effect of using this type of keratolytic agent.


Q: Can I use Compound W if I am breastfeeding?

A: Official information states that professional consultation is advised before use during pregnancy and lactation. This precaution is in place because systemic absorption of the active ingredient remains a possibility, and the official guidance emphasizes that professional consultation may be necessary to assess individual circumstances.


Q: Is Compound W safe to use during pregnancy?

A: Official regulatory guidance states that professional consultation is advised before using the product during pregnancy. This precaution is advised because the active ingredient, salicylic acid, has the potential for some systemic absorption, and professional consultation may be necessary to evaluate the specific situation.


Q: Can I use a pumice stone or file while treating the wart with Compound W?

A: The regulatory protocol for using the product generally specifies soaking the affected area in warm water for approximately five minutes prior to cleaning and drying the application site. This preparatory step is intended to soften the tissue and may involve the removal of the softened dead skin, which is often done with a file or pumice stone.


Q: Is the evidence for Compound W's effectiveness strong?

A: Research has explored the role of the active agent in treating hyperkeratotic conditions like warts through various studies, including Phase 3 Randomized Controlled Trials. The FDA and other government bodies recognize the active ingredient, salicylic acid, as an established treatment for this purpose, which supports its Over-the-Counter status.


Q: What happens if Compound W touches healthy skin?

A: Official directions strictly mandate avoiding contact with surrounding normal skin. If the product does touch healthy skin, because it is a keratolytic agent, it is designed to dissolve tissue and may cause localized irritation, peeling, or a chemical burn.


Q: Can I use Compound W if I have a viral illness like the flu or chickenpox?

A: Use of this medicine is contraindicated if a patient, particularly a child or teenager, has or is recovering from Influenza or Chickenpox. This restriction is due to the potential increased risk of a serious, though rare, condition known as Reye's syndrome linked to systemic salicylate exposure in these cases.


Q: Can I use Compound W if I am taking oral aspirin or other pain relievers?

A: The official regulatory information cautions against the simultaneous use of topical salicylic acid with oral aspirin or other salicylate-containing medicines. This is because using both products can contribute to an increased total systemic exposure to the salicylate compound.


Q: What should I do if I accidentally swallow a small amount of the liquid?

A: The product is strictly for external, topical use. Given the documented risk of systemic toxicity (salicylism) from absorption, if accidental ingestion occurs, the official product labels contain directions for seeking medical help or contacting a Poison Control Center.

How should Compound W be stored and disposed of?

The storage and disposal of this topical salicylic acid medicine must strictly follow regulatory guidance to ensure safety and product stability.

Requirement Category Official Regulatory Statement
Storage Temperature Store at room temperature (20 C to 25 C). Avoid excessive heat up to 37 C (99 F).
Handling Requirements Product is flammable. Must be kept away from fire or flame and away from heat and moisture.
Container Integrity Cap bottle tightly or keep the tube closed tightly when not in use to prevent solvent evaporation and product solidification.
Child Protection Keep out of reach of children.
Disposal Discard the product once the treatment is complete and the wart is removed. Dispose of unused medicine via a drug take-back program or follow FDA household trash guidelines (e.g., mixing with undesirable material, sealing, and placing in trash).

The official labeling defines that the medicine must be protected from high temperatures and ignition sources due to its composition. Stability is maintained by explicit instructions to seal the container tightly to prevent solvent loss and product hardening. The regulatory profile mandates that the medicine be kept out of reach of children for safety.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Compound W found in:

A-Z Index: